LAVA Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de LAVA Therapeutics es Steve Hurly, nombrado en Jun 2019, tiene una permanencia de 5.42 años. posee directamente un 0.019% de las acciones de la empresa, con un valor de $8.05K. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 3.8 años, respectivamente.

Información clave

Steve Hurly

Chief Executive Officer (CEO)

US$814.4k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	5.4yrs
Participación del CEO	0.02%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

Revenues Working Against LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Share Price Following 25% Dive

Jun 02

LAVA Therapeutics (NASDAQ:LVTX) Has Debt But No Earnings; Should You Worry?

Mar 01

LAVA Therapeutics: Assessing A Promising Innovator

Oct 18

LAVA Therapeutics GAAP EPS of -$0.31 beats by $0.30, revenue of $0.47M beats by $0.11M

Sep 13

CEO

Steve Hurly (56 yo)

5.4yrs

Permanencia

US$814,399

Compensación

Mr. Stephen Allen Hurly, also known as Steve, MSc, MBA, serves as Chief Executive Officer, President and Executive Director at Lava Therapeutics N.V. since June 2019. Mr. Hurly was Chief Executive Officer...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stephen Hurly	CEO, President & Executive Director	5.4yrs	US$814.40k	0.019% $ 8.0k
Fred Powell	Chief Financial Officer	2yrs	sin datos	0.25% $ 104.6k
Hans van der Vliet	Chief Scientific Officer	7.8yrs	sin datos	0.29% $ 124.5k
Amy Garabedian	General Counsel & Corporate Secretary	3.3yrs	sin datos	0.034% $ 14.2k
Wouter Hunnik	VP & Head of Human Resources	3yrs	sin datos	sin datos
Ton Adang	Chief Development Officer	7.3yrs	sin datos	0.024% $ 10.3k
Charles Morris	Chief Medical Officer	1.8yrs	sin datos	0% $ 0

3.3yrs

Permanencia media

57.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LVTX se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Stephen Hurly	CEO, President & Executive Director	5.4yrs	US$814.40k	0.019% $ 8.0k
James Noble	Independent Non-Executive Director	2.4yrs	US$52.50k	0% $ 0
Karen Wilson	Independent Non-Executive Director	3.7yrs	US$55.00k	0.038% $ 16.1k
James Allison	Member of Advisory Board	4.8yrs	sin datos	sin datos
Jay Backstrom	Non-Executive Director	2.4yrs	US$47.00k	0% $ 0
Kapil Dhingra	Non-Executive Chairman	3.8yrs	US$82.63k	0.11% $ 48.3k
Christy Oliger	Non-Executive Director	1.7yrs	US$37.85k	0% $ 0
Andrea van Elsas	Chairman of Advisory Board	6.6yrs	sin datos	sin datos
Padmanee Sharma	Member of Advisory Board	4.8yrs	sin datos	sin datos
K. Wittrup	Member of Advisory Board	no data	sin datos	sin datos
Dieter Kabelitz	Member of Advisory Board	no data	sin datos	sin datos
Madhav Dhodapkar	Member of Advisory Board	no data	sin datos	sin datos

3.8yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de LVTX se considera experimentada (3.8 años de antigüedad promedio).

LAVA Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

LAVA Therapeutics N.V., Annual General Meeting, Jun 19, 2024

LAVA Therapeutics N.V., Annual General Meeting, Jun 14, 2023

LAVA Therapeutics N.V. Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

LAVA Therapeutics N.V. Announces Board Changes

Less than half of directors are independent

LAVA Therapeutics N.V. Announces Appointment of Fred M. Powell as Chief Financial Officer

Recent updates

Second quarter 2024 earnings released: US$0.31 loss per share (vs US$0.48 loss in 2Q 2023)

Consensus revenue estimates increase by 51%, EPS downgraded

LAVA Therapeutics N.V., Annual General Meeting, Jun 19, 2024

Revenues Working Against LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Share Price Following 25% Dive

First quarter 2024 earnings released: US$0.021 loss per share (vs US$0.53 loss in 1Q 2023)

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

LAVA Therapeutics N.V. Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052

LAVA Therapeutics (NASDAQ:LVTX) Has Debt But No Earnings; Should You Worry?

New major risk - Share price stability

New minor risk - Share price stability

Consensus revenue estimates fall by 50%

Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.039 profit in 3Q 2022)

Consensus revenue estimates increase by 101%

Consensus EPS estimates fall by 12%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

LAVA Therapeutics N.V. Provides Updates on Clinical Programs and Extends the Cash Runway

First quarter 2023 earnings released: US$0.53 loss per share (vs US$0.41 loss in 1Q 2022)

LAVA Therapeutics N.V., Annual General Meeting, Jun 14, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

LAVA Therapeutics N.V. Announces Initial Data from the Ongoing Phase 1/2A Clinical Trial of Lava-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium

LAVA Therapeutics N.V. Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

LAVA Therapeutics N.V. Announces Board Changes

LAVA Therapeutics N.V. Announces Updated Data from the Phase 1/2A Clinical Trial of LAVA-051 at the 64th American Society of Hematology Annual Meeting and Exposition

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 47%

Less than half of directors are independent

LAVA Therapeutics N.V. Announces Appointment of Fred M. Powell as Chief Financial Officer

LAVA Therapeutics: Assessing A Promising Innovator

Consensus revenue estimates increase by 580%

Consensus revenue estimates increase by 116%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

LAVA Therapeutics GAAP EPS of -$0.31 beats by $0.30, revenue of $0.47M beats by $0.11M

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

LAVA Therapeutics N.V. Announces Board Changes

LAVA Therapeutics N.V., Annual General Meeting, Jun 15, 2022

Consensus forecasts updated

LAVA Therapeutics N.V. to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

LAVA Therapeutics N.V., Annual General Meeting, Jun 15, 2022

Consensus revenue estimates increase by 686%

LAVA Therapeutics N.V. Announces the Resignation of Ed Smith as Chief Financial Officer

Lava Therapeutics N.V. Announces FDA IND Clearance for Lava-051 for the Treatment of Hematologic Malignancies

LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Less than half of directors are independent

LAVA Therapeutics N.V. Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022

LAVA Therapeutics N.V. Announces Dosing of the First Patient in the Phase 1/2A Clinical Trial of LAVA-1207 in Patients with Metastatic Castration-Resistant Prostate Cancer

LAVA Therapeutics N.V. Presents Preclinical Data on its Gammabody™ T Cell Engager Platform at the 21st Annual PepTalk Conference

Consensus forecasts updated

Third quarter 2021 earnings released: €0.29 loss per share

Consensus revenue estimates increase to €909.0k

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad